A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes.

abstract：:We have shown a new phenomenon demonstrating that BALB/c female mice mated to C57BL/6 males during a year (7-10 pregnancies) develop AIDS-like disease or acute leukemia after an additional immunization with fixed ConA activated paternal (C57BL/6) lymphocytes. The AIDS-like disease is sexually and vertically transmissi...

journal_title：Leukemia

authors： Ter-Grigorov V,Krifuks O,Liubashevsky E,Nyska A,Toder V,Trainin Z

更新日期：1997-04-01 00:00:00

abstract：:The MDM2 gene is a gene whose product binds to p53 and regulates its function. Amplification of MDM2 has been found in human sarcomas, where it leads to inactivation of p53. In 64 cases of generally advanced myelodysplastic syndromes, we found no amplification or rearrangement of MDM2 gene by Southern analysis. MDM2 R...

journal_title：Leukemia

authors： Preudhomme C,Quesnel B,Vachee A,Lepelley P,Collyn-D'Hooghe M,Wattel E,Fenaux P

更新日期：1993-08-01 00:00:00

abstract：:The efficacy of antifungal prophylaxis with itraconazole capsules and its serum concentrations were evaluated in patients intensively treated for acute leukaemia. A consecutive group of patients without systemic antifungal prophylaxis (January 1993 to August 1994, period 1) was compared with another consecutive group ...

journal_title：Leukemia

authors： Glasmacher A,Molitor E,Hahn C,Bomba K,Ewig S,Leutner C,Wardelmann E,Schmidt-Wolf IG,Mezger J,Marklein G,Sauerbruch T

更新日期：1998-09-01 00:00:00

abstract：:In chronic lymphocytic leukemia (CLL), stabilizing mutations of NOTCH1, affecting up to 10-15% of cases, have been associated to poor prognosis, disease progression and refractoriness to chemotherapy. NOTCH1 mutations are significantly overrepresented in trisomy 12 CLL, a disease subset frequently expressing CD49d, th...

journal_title：Leukemia

authors： Benedetti D,Tissino E,Pozzo F,Bittolo T,Caldana C,Perini C,Martorelli D,Bravin V,D'Agaro T,Rossi FM,Bomben R,Santinelli E,Zaja F,Pozzato G,Chiarenza A,Di Raimondo F,Del Poeta G,Rossi D,Gaidano G,Dal Bo M,Gattei V

更新日期：2018-03-01 00:00:00

abstract：:We have previously shown that chronic lymphocytic leukemia (CLL) B cells secrete vascular endothelial growth factor (VEGF) in vitro, have constitutively active VEGF receptors R1 and R2, and respond to exogenous VEGF by specifically upregulating Mcl-1 and XIAP in association with decreased cell death. We found that epi...

journal_title：Leukemia

authors： Lee YK,Shanafelt TD,Bone ND,Strege AK,Jelinek DF,Kay NE

更新日期：2005-04-01 00:00:00

abstract：:Calicheamicin-conjugated humanized anti-CD33 mouse monoclonal antibody, CMA-676, has recently been introduced to clinics as a promising drug to treat patients with acute myeloid leukemia (AML) in relapse. However, the mechanism of action of CMA-676 has not been well elucidated. The cytotoxic effect of CMA-676 on HL60,...

journal_title：Leukemia

authors： Naito K,Takeshita A,Shigeno K,Nakamura S,Fujisawa S,Shinjo K,Yoshida H,Ohnishi K,Mori M,Terakawa S,Ohno R

更新日期：2000-08-01 00:00:00

abstract：:Bortezomib (V) was combined with thalidomide (T) and dexamethasone (D) in a phase I/II trial to determine dose-limiting toxicities (DLT's) and clinical activity of the VTD regimen in 85 patients with advanced and refractory myeloma. The starting dose of V was 1.0 mg/m(2) (days 1, 4, 8, 11, every 21 day) with T added f...

journal_title：Leukemia

authors： Pineda-Roman M,Zangari M,van Rhee F,Anaissie E,Szymonifka J,Hoering A,Petty N,Crowley J,Shaughnessy J,Epstein J,Barlogie B

更新日期：2008-07-01 00:00:00

abstract：:The mesenchymal stroma has been shown to play a crucial role in the development of multiple myeloma, partly by secretion of interleukin (IL)-6, that serves as a growth factor for myeloma cells. However, it is still unclear which other stromal molecules are involved in the pathogenesis of this disease. We chose, as a m...

journal_title：Leukemia

authors： Shoham T,Sternberg D,Brosh N,Krupsky M,Barda-Saad M,Zipori D

更新日期：2001-07-01 00:00:00

abstract：:Osteopontin (OPN) is a multifunctional bone matrix glycoprotein that is involved in angiogenesis, cell survival and tumor progression. In this study we show that human myeloma cells directly produce OPN and express its major regulating gene Runx2/Cbfa1. The activity of Runx2/Cbfa1 protein in human myeloma cells has al...

journal_title：Leukemia

authors： Colla S,Morandi F,Lazzaretti M,Rizzato R,Lunghi P,Bonomini S,Mancini C,Pedrazzoni M,Crugnola M,Rizzoli V,Giuliani N

更新日期：2005-12-01 00:00:00

abstract：:We previously demonstrated that the EVI-1 gene was transcriptionally activated in the 3q21q26 syndrome and chromosomal breakpoints at 3q26 were clustered within 400 Kb of the EVI-1 gene. Since thrombocytosis is often observed in the 3q21q26 syndrome, we first mapped the thrombopoietin (TPO) gene and then we examined f...

journal_title：Leukemia

authors： Suzukawa K,Satoh H,Taniwaki M,Yokota J,Morishita K

更新日期：1995-08-01 00:00:00

abstract：:A single dominant gene Tlsm-1 was found to determine the type of spontaneous lymphomas to be T in the cross between AKR/Ms and SL/Kh. Microsatellite analysis mapped Tlsm-1 at the position 61 cM from centromere of Chr. 7. Study of this segment of T-lymphoma prone AKXD Rl strains also showed association of Tlsm-1 with T...

journal_title：Leukemia

authors： Hiai H,Yamada Y,Shisa H,Kamoto T,Abujiang P,Lu LM

更新日期：1997-04-01 00:00:00

abstract：:Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval. The first-in-class drug ibrutinib creates possibilities for an era of chemotherapy-free management of B-cell malignancies,...

journal_title：Leukemia

authors： Wen T,Wang J,Shi Y,Qian H,Liu P

更新日期：2020-10-29 00:00:00

abstract：:Despite the presence of tumor antigens, the paucity of clinically significant T-cell mediated immune responses against human tumors is striking. This may, in part, be because of the inability of cancer cells to function as efficient antigen-presenting cells. For full activation, T cells must receive two signals delive...

journal_title：Leukemia

authors： Gribben JG,Cardoso AA,Schultze JL,Nadler LM

更新日期：1997-05-01 00:00:00

abstract：:In this study, we determined the respective roles of RelA and RelB NF-κB subunits in Epstein-Barr virus (EBV)-transformed B cells. Using different EBV-immortalized B-cell models, we showed that only RelA activation increased both survival and cell growth. RelB activity was induced secondarily to RelA activation and re...

journal_title：Leukemia

authors： Chanut A,Duguet F,Marfak A,David A,Petit B,Parrens M,Durand-Panteix S,Boulin-Deveza M,Gachard N,Youlyouz-Marfak I,Bordessoule D,Feuillard J,Faumont N

更新日期：2014-04-01 00:00:00

abstract：:Dasatinib treatment markedly increases the number of large granular lymphocytes (LGLs) in a proportion of Ph+ leukemia patients, which associates with a better prognosis. The lymphocytosis is predominantly observed in cytomegalovirus (CMV)-seropositive patients, yet detectable CMV reactivation exists only in a small f...

journal_title：Leukemia

authors： Ishiyama K,Kitawaki T,Sugimoto N,Sozu T,Anzai N,Okada M,Nohgawa M,Hatanaka K,Arima N,Ishikawa T,Tabata S,Onaka T,Oka S,Nakabo Y,Amakawa R,Matsui M,Moriguchi T,Takaori-Kondo A,Kadowaki N

更新日期：2017-01-01 00:00:00

abstract：:The p21MDA6 gene product induces cell cycle arrest in p53-null human leukemic cells exposed to differentiation stimuli. We employed an HL-60 cell line stably transfected with a p21MDA6 antisense construct to compare the effects of p21MDA6 dysregulation on the response of myeloid leukemia cells to differentiating and c...

journal_title：Leukemia

authors： Freemerman AJ,Vrana JA,Tombes RM,Jiang H,Chellappan SP,Fisher PB,Grant S

更新日期：1997-04-01 00:00:00

abstract：:Neutropenia-related fungal infections can be life-threatening despite antifungal therapy. We evaluated the role of recombinant granulocyte colony-stimulating factor (rG-CSF)-elicited white blood cell (WBC) transfusions in patients with neutropenia-related fungal infections. Adult patients with hematologic malignancies...

journal_title：Leukemia

authors： Dignani MC,Anaissie EJ,Hester JP,O'Brien S,Vartivarian SE,Rex JH,Kantarjian H,Jendiroba DB,Lichtiger B,Andersson BS,Freireich EJ

更新日期：1997-10-01 00:00:00

abstract：:We previously reported the fusion of the TEL gene to the Syk gene in myelodysplastic syndrome with t(9;12)(q22;p12). TEL-Syk fusion transformed interleukin-3 (IL-3)-dependent murine hematopoietic cell line BaF3 to growth factor independence. Here, we investigate the intracellular signal transduction of the stable tran...

journal_title：Leukemia

authors： Kanie T,Abe A,Matsuda T,Kuno Y,Towatari M,Yamamoto T,Saito H,Emi N,Naoe T

更新日期：2004-03-01 00:00:00

abstract：:Different normal and malignant human B-cell populations were studied with a twofold aim: to define which cytokines are produced in vivo, and to assess the relationship between cytokine production and kinetic state. To analyse normal B-cells representative of different stages of activation and proliferation in vivo, we...

journal_title：Leukemia

authors： Schena M,Gaidano G,Gottardi D,Malavasi F,Larsson LG,Nilsson K,Caligaris-Cappio F

更新日期：1992-02-01 00:00:00

abstract：:To develop an effective immunotherapy for B-lineage acute lymphoblastic leukemia (ALL), bispecific monoclonal antibodies (bsAb) were raised by cell fusion of two hybridoma cell lines secreting CD3 and CD19 antibodies. The resulting bispecific antibody contains two different specificities within a single antibody molec...

journal_title：Leukemia

authors： Csóka M,Strauss G,Debatin KM,Moldenhauer G

更新日期：1996-11-01 00:00:00

abstract：:The inhibition of nuclear factor kappa B (NF-kappaB) by, for instance, curcumin is becoming an important new approach in combination with chemotherapy or irradiation for the treatment of a variety of cancers including haematological malignancies. A dose-limiting side effect of anticancer therapy in the gastrointestina...

journal_title：Leukemia

authors： van't Land B,Blijlevens NM,Marteijn J,Timal S,Donnelly JP,de Witte TJ,M'Rabet L

更新日期：2004-02-01 00:00:00

abstract：:The myeloproliferative neoplasms (MPNs) are characterized by hematopoietic stem/progenitor cell (HSPC) expansion and overproduction of mature blood cells. The JAK2V617F mutation is present in hematopoietic cells in a majority of patients with MPNs, but the mechanism(s) responsible for MPN stem cell expansion remain in...

journal_title：Leukemia

authors： Zhan H,Ma Y,Lin CH,Kaushansky K

更新日期：2016-12-01 00:00:00

abstract：:Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by clonal proliferation of plasma cells and a heterogenous genomic landscape. Copy number and structural changes due to chromosomal instability (CIN) are common features of MM. In this review, we describe how primary and secondary genetic event...

journal_title：Leukemia

authors： Neuse CJ,Lomas OC,Schliemann C,Shen YJ,Manier S,Bustoros M,Ghobrial IM

更新日期：2020-11-01 00:00:00

abstract：:Although current treatments can induce clinical complete remissions in the vast majority of patients with indolent lymphoma, most of them actually relapse, because of the persistence of residual tumor cells which are undetectable using conventional diagnostic procedures. Polymerase chain reaction (PCR)-based methods a...

journal_title：Leukemia

authors： Corradini P,Ladetto M,Pileri A,Tarella C

更新日期：1999-11-01 00:00:00

abstract：:The molecular basis for autonomous growth of malignant forms of human T lymphocytes is not known. It can be investigated by functional responses of malignant cells in comparison with untransformed counterparts. At least two pathways (the CD2 and CD3 pathways) of human T-cell activation have been recently defined on th...

journal_title：Leukemia

authors： Schirren CA,Völpel H,Meuer SC

更新日期：1992-06-01 00:00:00

abstract：:Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells. It is classified as either primary PCL occurring at diagnosis or as secondary PCL in patients with relapsed/refractory myeloma. Primary PCL is a distinct clinic-pathological entity with dif...

journal_title：Leukemia

authors： Fernández de Larrea C,Kyle RA,Durie BG,Ludwig H,Usmani S,Vesole DH,Hajek R,San Miguel JF,Sezer O,Sonneveld P,Kumar SK,Mahindra A,Comenzo R,Palumbo A,Mazumber A,Anderson KC,Richardson PG,Badros AZ,Caers J,Cavo M,Le

更新日期：2013-04-01 00:00:00

abstract：:Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median age, 73.4 years) treated either with ATO+ all-trans retinoic acid (ATO/ATRA; n = 26), CTX/ATRA + ATO during ...

journal_title：Leukemia

authors： Kayser S,Rahmé R,Martínez-Cuadrón D,Ghiaur G,Thomas X,Sobas M,Guerci-Bresler A,Garrido A,Pigneux A,Gil C,Raffoux E,Tormo M,Vey N,de la Serna J,Salamero O,Lengfelder E,Levis MJ,Fenaux P,Sanz MA,Platzbecker U,Schlen

更新日期：2020-09-01 00:00:00

abstract：:Chronic lymphocytic leukemia (CLL) cells with aggressive clinical properties express lipoprotein lipase (LPL), which generates activating ligands for the nuclear receptor peroxisome proliferator activated receptor (PPAR)α and allows fatty acids to be used as fuel. However, the role of PPARα in CLL is unclear. PPARα wa...

journal_title：Leukemia

authors： Spaner DE,Lee E,Shi Y,Wen F,Li Y,Tung S,McCaw L,Wong K,Gary-Gouy H,Dalloul A,Ceddia R,Gorzcynski R

更新日期：2013-04-01 00:00:00

abstract：:Patients with chronic lymphocytic leukemia (CLL) have defects in both cellular and humoral immunity. Since CD152 (CTLA-4) plays a critical role in downregulating T-cell responses, we studied the expression of surface and cytoplasmic CD152 (sCD152 and cCD152, respectively) in freshly isolated T cells from treatment-naï...

journal_title：Leukemia

authors： Motta M,Rassenti L,Shelvin BJ,Lerner S,Kipps TJ,Keating MJ,Wierda WG

更新日期：2005-10-01 00:00:00

abstract：:Jumping translocations (JT) are characterized by the relocalization of the same part of a donor to several recipient chromosomes. Although JT occasionally are constitutional, most are associated with hematologic malignancies. In such cases, JT usually arise during disease progression and are associated with poor progn...

journal_title：Leukemia

authors： Andreasson P,Höglund M,Jonson T,Békàssy A,Mitelman F,Johansson B

更新日期：1998-09-01 00:00:00